Stratasys Creates 3...
Health Care: Drugs
Aegerion Pharmaceuticals Inc. (AEGR: NASDAQ)
$58.25 -1.77 | -2.95%
05/22/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 37.17M | 26.37M | 44.10M | 1.43M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 83.75M | 74.08M | 44.61M | 1.97M |
| Property, Plant & Equipment, Gross | 1.42M | 623.31K | 93.60K | 81.87K |
| Accumulated Depreciation & Depletion | 276.00K | 96.96K | 77.12K | 67.14K |
| Property, Plant & Equipment, Net | 1.14M | 526.35K | 16.47K | 14.73K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 198.00K | 965.19K | 1.12M | 670.20K |
| Total Non-Current Assets | 1.34M | 1.49M | 1.14M | 684.93K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 85.09M | 75.57M | 45.75M | 2.65M |
| Accounts Payable | 4.95M | 2.80M | 3.15M | 403.60K |
| Short Term Debt | 3.02M | 1.88M | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 164.14K | 1.03M | 1.99M |
| Total Current Liabilities | 16.93M | 9.40M | 4.67M | 22.84M |
| Long Term Debt | 7.59M | 8.12M | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 173.00K | 841.43K | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 7.76M | 8.97M | 0.00 | 49.94M |
| Total Liabilities | 24.69M | 18.37M | 4.67M | 72.78M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 60.40M | 57.20M | 41.08M | -70.13M |
| Common Par | 25.00K | 21.30K | 17.74K | 4.42K |
| Additional Paid In Capital | 253.21M | 187.69M | 131.55M | 648.51K |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -192.72M | -130.46M | -90.99M | -70.86M |
| Treasury Stock | 0.00 | -373.00 | -373.00 | -373.00 |
| Other Equity Adjustments | -112.00K | -48.00K | 500.02K | 80.76K |
| Total Capitalization | 67.99M | 65.33M | 41.08M | -70.13M |
| Total Equity | 60.40M | 57.20M | 41.08M | -70.13M |
| Total Liabilities & Stock Equity | 85.09M | 75.57M | 45.75M | 2.65M |
| Total Common Shares Outstanding | 25.49M | 21.20M | 17.64M | 16.85M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 104.00K | 103.76K | 103.76K | 0.00 |
| Basic Weighted Shares Outstanding | 23.56M | 19.41M | 11.08M | 11.80M |
| Diluted Weighted Shares Outstanding | 23.56M | 19.41M | 11.08M | 11.80M |
| Number of Employees | 98 | 33 | 16 | NA |
| Number of Part-Time Employees | 0 | 0 | 0 | NA |
Portfolios with AEGR
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusal Vol...
- ContributorStocks With Big Insider Buy...
Latest AEGR Headlines from TheStreet
- Aegerion Stock Falls On Unusually High Volume (AEGR) 05.17.13 | 12:05 pm
- 4 Stocks Improving Performance Of The Health Care Sector 05.16.13 | 01:05 pm
- Biotech Is Where the Bucks Are 05.09.13 | 06:05 am
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program 05.03.13 | 04:05 pm
- Aegerion Pharmaceuticals Announces Presentation At The Bank Of America Merrill Lynch 2013 Healthcare Conference 05.03.13 | 08:05 am
- Aegerion Pharmaceuticals Announces First-Quarter 2013 Financial Results 04.30.13 | 07:04 am
- Anne VanLent Appointed To Aegerion Pharmaceuticals' Board Of Directors 04.29.13 | 07:04 am
- Aegerion Pharmaceuticals Announces Presentation At The Needham Healthcare Conference 04.25.13 | 04:04 pm
- Aegerion Pharmaceuticals To Announce First Quarter 2013 Financial Results On Tuesday, April 30 04.16.13 | 08:04 am
- Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program 04.03.13 | 04:04 pm
Press Releases for AEGR
- Insmed Appoints Will Lewis As President And Chief Executive Officer - PR Newswire 09.11.12 | 08:09 am
- Aegerion Pharmaceuticals Chief Executive Officer Marc D. Beer (Video: Business Wire) - Business Wire 09.29.11 | 08:09 am
Partner Headlines for AEGR
- Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed - Seeking Alpha 05.14.13 | 10:05 am
- Insider Buying Trends: Are These Cash Rich Companies Ready To Rally? - Seeking Alpha 03.15.13 | 09:03 am
- UPDATE: Canaccord Genuity Raises PT to $44 on Aegerion Pharmaceuticals on Encouraging Sales Data - Benzinga 03.07.13 | 01:03 pm
- UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake - Benzinga 03.06.13 | 01:03 pm
- Pre-Market Earnings Report for March 6, 2013 : SPLS, BF/B, AEO, TFM, BIG, AEGR, HOV, WD, TRK, QRE, WILN, MFB - NASDAQ 03.05.13 | 09:03 pm
- Calendar Spreads On Intuitive Surgical, Riverbed Technology And Sandisk - Seeking Alpha 10.19.12 | 09:10 am
- Benzinga Mid-Day Market Update - Benzinga 10.17.12 | 12:10 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review of Lomitapide NDA - Benzinga 08.14.12 | 09:08 am
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
